Trial Profile

A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-mesothelin chimeric antigen receptor T cell therapy Atara Biotherapeutics (Primary) ; Cyclophosphamide
Indications Mesothelioma
Focus Adverse reactions; First in man
Sponsors Atara Biotherapeutics

25 Jul 2024 Status changed from recruiting to active, no longer recruiting.
18 Jun 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
18 Jun 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com